Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for managing type 2 diabetes and obesity due to their profound systemic metabolic effects. However, alongside these benefits, concerns have arisen about potential dermatological side effects. Rapid weight reduction from GLP-1 RAs has been linked to loss of facial fat (“Ozempic face”), skin laxity, and an aging appearance. Evidence from human studies suggests a connection between GLP-1 RA–induced rapid weight loss and decreased collagen and elastin, reduced hydration, and even hair loss (telogen effluvium) in a subset of patients. Complementary in vitro findings suggest that these changes may result from nutritional deficiencies, elevated oxidative stress, and mitochondrial dysfunction.Emerging data indicate that methylene blue (MB), a mitochondrial-targeted redox modulator, exerts broad protective effects on skin and hair follicles by enhancing mitochondrial respiration, reducing reactive oxygen species, and stimulating collagen and extracellular matrix renewal. MB has also been shown to mitigate cellular cytotoxicity induced by metabolic stressors, including GLP-1 RAs, while promoting follicular stem cell viability and regeneration. When combined with ceramides, which restore the epidermal lipid barrier and improve hydration, MB offers a mechanistically complementary approach to address GLP-1–related skin thinning and barrier dysfunction. This review integrates recent advances on GLP-1 RA–induced dermatologic alterations with mechanistic insights into MB- and ceramide-mediated protection, proposing a novel dual-target strategy to restore dermal resilience, collagen homeostasis, and hair follicle integrity in patients undergoing GLP-1 therapy.

• GLP-1 RAs can lead to visible skin aging, known as “Ozempic face”.

• Hair shedding is a common but reversible side effect driven by rapid weight loss.

• Underlying molecular mechanisms of GLP-1 RA on the skin and hair are multifactorial.

• How antioxidants like Methylene Blue can help preserve skin and hair health during GLP-1 RA treatments is discussed. 

• GLP-1

• Metheylene Blue

Zhan K, Cao K (2026) Mitigating GLP-1–Related Dermatologic Adverse Effects through Methylene Blue’s Antioxidant Action. Ann Clin Pathol 13(1): 1186.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an incretin-based class of medications initially developed for type 2 diabetes and are now also approved for obesity treatment [1]. By mimicking the gut hormone GLP-1, these agents stimulate glucose-dependent insulin secretion, suppress glucagon (a key hormone that regulates blood sugar levels), slow gastric emptying, and influence central appetite centers to reduce food intake [2]. Consequently, GLP-1 RAs, such as semaglutide and liraglutide, can lead to substantial weight loss along with improved glycemic control and reduced cardiovascular risk [2]. This effectiveness has resulted in the unprecedented popularity of GLP-1 RAs for weight management in recent years.

However, the rapid and significant weight loss induced by GLP-1 RAs has also highlighted several dermatological side effects. Patients undergoing long-term GLP-1 RA therapy have reported various adverse skin manifestations. Some of these are directly related to the medication (e.g., injection site reactions, drug-induced immune responses), but most are secondary to the weight loss and metabolic changes (e.g., loss of facial fat, skin sagging, hair shedding), [3]. For instance, the term “Ozempic face” has entered popular discourse to describe the gaunt, aged facial appearance resulting from GLP-1 RA-associated fat loss in the midface and temples [2,3]. Concurrently, dermatologists are noting increased cases of significant hair loss (telogen effluvium) in patients who experienced rapid weight reduction on these drugs [4]. These emerging dermatologic issues underscore the importance of awareness among healthcare providers and patients, as they can significantly impact quality of life and may necessitate co-management with dermatology specialists.

In this review, we discuss mechanisms by which GLP-1 RAs may impair skin integrity, collagen synthesis, hydration, and mitochondrial function, all factors that contribute to skin aging. In addition, we present a section on potential approaches to prevent or mitigate GLP-1 RA-related skin issues, focusing on the use of over-the-counter antioxidants, such as methylene blue, aimed at preserving skin health during GLP-1 RA therapy.

Changes in Skin Integrity and Elasticity (“Ozempic Face”)

A key dermatologic concern with GLP-1 RAs stems from the rapid changes in body composition they induce. Accelerated fat loss, particularly in the face, can compromise skin firmness and integrity. As subcutaneous fat diminishes, the structural support for overlying skin weakens, leading to looseness, hollowing, and accentuation of wrinkles, features commonly referred to as “Ozempic face.” Even modest reductions in midfacial fat or buccal volume can create deeper nasolabial folds, sunken eyes, and sagging jowls, all of which resemble accelerated facial aging [3] (Figure 1A).

Figure 1: Mechanisms of Undesired Skin and Hair Effects Associated with GLP-1 Receptor Agonists (GLP-1 RAs) (A) GLP-1 RA treatment induces rapid weight loss, which contributes to a range of dermatologic side effects collectively referred to as “undesired skin effects.” These include facial volume loss (“Ozempic Face”), dehydration, thinning skin, sagging jowls, and hair loss (telogen effluvium). (B) Several mechanistic pathways contribute to these side effects. From Left to right: Nutrient Deficiency. Caloric restriction and altered metabolism may result in reduced intake or absorption of essential vitamins and minerals (e.g., zinc), impairing collagen and elastin synthesis. Mitochondrial Dysfunction. Catabolic stress and metabolic shifts lead to increased oxidative stress and impaired mitochondrial function, contributing to tissue aging. Hormonal Changes. Reductions in IGF-1, thyroid hormones, estrogen, and testosterone can lead to skin thinning and dehydration. Loss of Fat Mass. Decreased leptin levels due to reduced subcutaneous fat adversely affect hair follicle function and wound healing capacity.

Skin laxity following weight loss is well documented in post-bariatric patients, where rapid fat reduction outpaces the skin’s ability to contract. Histological studies have shown decreased dermal collagen density and disorganized elastic fibers, resulting in reduced tensile strength [5]. Although comparable biopsy data are limited in GLP-1 RA users, similar mechanisms likely apply. Fat loss reduces adipose-derived collagen synthesis (especially type VI collagen), while caloric restriction transiently suppresses fibroblast activity. Consequently, dermal collagen content and skin elasticity decline, yielding thinner, less resilient skin.

In summary, GLP-1 RA–induced weight loss can accelerate visible skin aging by depleting subcutaneous fat and structural proteins essential for firmness and elasticity. These cosmetic effects, most evident in middle-aged individuals, can be psychologically distressing and,in some cases, lead patients to discontinue otherwise effective GLP-1 therapy.

Skin Dehydration and Nutrition Deficiencies

Hydration is a key component of skin health that may be indirectly affected by GLP-1 RA treatment. Many patients report drier or less supple skin, which can be attributed to several factors (Figure 1A). GLP-1 RAs often cause nausea, vomiting, and appetite suppression, leading to reduced fluid intake and mild dehydration, which manifests as dry, dull skin [6]. Decreased oral intake of water-rich foods and reduced sebaceous gland activity during rapid weight loss may further reduce skin moisture and alter surface lipids [7].

Another factor is nutrition: weight loss, especially if rapid, can lead to deficiencies in essential nutrients (fats, vitamins, zinc, etc.) that are important for skin hydration and barrier lipids. If patients inadvertently consume very low-fat diets while on GLP-1 RAs (due to reduced appetite), they may impair the skin’s ability to produce its natural oils and lipid components, particularly ceramides. Ceramides are crucial molecules in the stratum corneum that maintain barrier function and prevent water loss. A deficiency in dietary essential fatty acids or overall caloric malnutrition can cause xerosis (dry, scaly skin) in extreme cases. Even moderate changes could shift someone from having well-hydrated skin to experiencing dryness.

Supportive evidence comes from general skin health studies: Adequate hydration and intake of antioxidants and micronutrients correlate with better skin elasticity and moisture retention [8]. For example, Manzoni et al. reviewed that a balanced diet and sufficient water intake support collagen synthesis and help mitigate oxidative stress in the skin, thereby maintaining hydration and delaying aging [8]. In practical terms, patients on GLP-1 RAs should be advised to drink plenty of fluids and use moisturizers to reinforce their skin barrier. In summary, while GLP-1 RAs do not directly “dry out” the skin in a pharmacologic sense, the side effects and lifestyle changes associated with their use can compromise skin hydration and barrier function, warranting proactive measures to keep the skin moisturized.

Hair Loss

Dermatologists have recently observed a higher incidence of hair shedding in patients on GLP-1 RAs, particularly those experiencing rapid weight loss [9]. The most common presentation is telogen effluvium, a stress induced condition in which hair follicles prematurely transition from the growth (anagen) phase to the resting/ shedding (telogen) phase. Clinically, patients report increased shedding a few months after initiating therapy, often manifesting as diffuse thinning or hair coming out during brushing or showering. This reaction likely reflects the physiological stress of sudden weight reduction and transient nutritional deficiencies, factors well known to trigger telogen effluvium after bariatric surgery or crash dieting [10]. Recent research also points to a direct biological effect of GLP-1 signaling on hair follicle health. GLP-1 receptors are widely distributed across human tissues, including hair follicle stem cells (unpublished). Interestingly, exposure to low concentrations of GLP-1 was found to exert cytotoxic effects on hair follicle stem cells, suggesting that, beyond systemic metabolic stress, GLP-1 RAs may directly impair the regenerative capacity of the hair follicle.

These dermatologic effects induced by GLP-1 RAs can involve both direct drug actions and the indirect consequences of weight loss and metabolic changes. Several cellular and molecular mechanisms have been proposed (Figure 1B):

Nutrient State Change

GLP-1 RAs create a calorie deficit, leading to weight loss. Rapid weight loss essentially results in a controlled catabolic state, where the body breaks down fat (and to some extent lean mass) for energy. This condition can divert nutrients away from non-essential functions like hair growth and skin turnover. If protein intake is not adequately maintained, the body prioritizes vital organs over collagen production, potentially reducing collagen synthesis in the skin. Additionally, drastic reductions in body fat can lower levels of fat-soluble vitamins (A, D, E, K) and essential fatty acids, crucial for maintaining skin and hair health. For example, vitamin A and zinc are necessary for epidermal cell proliferation [11]; deficiencies may result in dry, rough skin.

Fat Mass Reduction

Adipose tissue is not just a fat store; it also houses and secretes hormones (like leptin and adiponectin) and growth factors that affect the skin. Leptin, for instance, can promote wound healing and hair follicle cycling. A sudden loss of fat mass results in decreased leptin levels. Low leptin has been associated with hair loss and delayed wound healing in some studies [12,13]. Additionally, adipose tissue contains adipose-derived stem cells in the dermal-subcutaneous junction that can differentiate into fibroblasts or other cells involved in skin repair [14]. Some dermatologists have speculated that with rapid fat depletion, these local stem cells may be less active (“turned off”), potentially impairing skin regeneration and collagen renewal [3].This concept was mentioned by aesthetic physicians observing Ozempic face – the idea that reduced facial fat might mean fewer signals to maintain dermal thickness, since facial fat pads and dermal fibroblasts crosstalk in maintaining youthful skin.

Mitochondrial Function and Oxidative Stress

Skin aging is closely linked to mitochondrial function in cells. Mitochondria generate the energy (ATP) required for collagen synthesis, cell division, and overall skin biosynthetic activity [15]. Caloric restriction, as induced by GLP-1 RAs, can have complex effects on mitochondria. Some data indicate that chronic caloric restriction may enhance mitochondrial efficiency and reduce reactive oxygen species, potentially slowing intrinsic aging [16]. Conversely, if weight loss occurs rapidly and is accompanied by stress, it might temporarily increase oxidative stress (from rapid fat oxidation) and could even diminish mitochondrial biogenesis in peripheral tissues [17]. Some studies suggest a potential downregulation of mitochondrial activity in peripheral tissues by GLP-1 RAs, which may contribute to symptoms such as fatigue and impaired tissue regeneration [2]. One might also extrapolate from related fields. For instance, in cases of malnutrition or eating disorders, skin and hair suffer due to impaired cellular energy metabolism [18]. It is plausible that some patients on GLP-1 RAs experience a milder version of this – their skin cells might not receive optimal energy or substrates, resulting in slower turnover and repair. This could present as a sallow complexion or delayed healing of minor skin damage. Additionally, thyroid hormone (which declines with weight loss) is a crucial regulator of mitochondrial function; low T3 could reduce mitochondrial activity in skin cells [19].

In summary, the mechanisms are multifactorial. Rapid weight loss is the central driver, bringing along downstream effects (nutrient deficits, hormonal changes, oxidative stress) that collectively impact skin and hair. The drug itself may exert subtle direct effects, but most negative dermatologic outcomes can be traced back to the consequences of weight and fat reduction. This understanding is useful because it highlights mitigation strategies: if we can support the skin through the stress of weight loss, we may reduce these side effects.

Considering the variety of dermatological issues that can arise from GLP-1 RA therapy, it is crucial to address how to prevent or mitigate these effects without compromising the metabolic benefits. In clinical practice, dermatologists and plastic surgeons have managed “Ozempic face” by using dermal fillers to restore volume or energy-based skin-tightening procedures, such as radiofrequency or ultrasound, to stimulate new collagen and tighten skin. Such interventions can partially reverse the aesthetic impacts by encouraging collagen synthesis and mechanically lifting sagging areas. Here, we explore several strategies and compounds, such as ceramides, methylene blue, and retinoids, all of which have shown promise in mitigating the skin-related side effects. These approaches are designed for simple, at-home skincare remedies rather than clinical interventions, making them easily accessible yet scientifically grounded. A comprehensive approach is recommended for severe cases, merging general skincare principles with specific interventions.

Supplementing Ceramide in skin moisturizers:

Emerging research suggests that GLP-1 RAs may reduce ceramide levels in the body [20]. For instance, the LiraFlame trial demonstrated that liraglutide downregulated several lipid species, including ceramides, in individuals with type 2 diabetes. Mechanistically, GLP 1 RAs may affect ceramide metabolism by modulating the gut microbiota and altering the activity of ceramide synthase enzymes [21]. However, ceramides are essential components of the skin’s outermost layer, where they help seal in moisture and defend against environmental stressors. When ceramide levels are depleted, whether due to systemic changes or medication effects, the skin barrier can become compromised, leading to dryness, irritation, and visible aging. Topical moisturizers enriched with ceramides can help restore these lipids and have been clinically shown to improve skin hydration, texture, and barrier function. In one study, a ceramide-containing cream significantly increased skin hydration within hours and outperformed placebo in reinforcing the skin barrier [5]. For individuals undergoing GLP-1 RA therapy, incorporating a daily ceramide-rich moisturizer, along with gentle, pH-balanced cleansers, can help counteract medication-associated skin dryness and scaling. These products deliver key lipid components that support water retention and repair barrier integrity. Dermatologists also recommend applying moisturizers immediately after bathing to lock in moisture and using humidifiers in dry environments to minimize transepidermal water loss.

Incorporating Methylene Blue-based skincare routines

In the skin, this relative mitochondrial lull induced by GLP1-RA treatment may accelerate cellular aging, reduce fibroblast function, and impair collagen synthesis and moisture retention. To counteract these mitochondrial and cellular effects, methylene blue (MB) has emerged as a promising intervention [22]. MB is a well-established synthetic compound widely used in research and medicine [22]. Recent studies have indicated that MB acts as a potent mitochondria-targeted antioxidant that enhances mitochondrial respiration, boosts ATP production, and lowers reactive oxygen species (ROS) [15-24]. These mechanisms are particularly relevant in the context of skin aging, where mitochondrial dysfunction contributes to oxidative damage, decreased extracellular matrix production, and impaired barrier function.

Preclinical studies have demonstrated that low-dose MB treatment rejuvenates aged human fibroblasts by increasing proliferation and delaying cellular senescence [24]. In 3D human skin equivalents, topical MB significantly increases dermal thickness, improves hydration, upregulates key extracellular matrix genes, including COL1A1 (collagen), COL3A1 (collagen), and ELN (elastin), and inhibits collagen degrading Matrix metalloproteinases (MMPs) [24]. Early clinical testing of MB-containing topical formulations has shown improvements in skin elasticity and hydration, as well as a reduction in fine wrinkles.

Importantly, MB exhibits excellent skin penetration, efficiently reaching both the epidermal and dermal layers without the need for chemical enhancers, owing to its small molecular weight (319 Da) and amphipathic nature. Its safety profile is well established, MB is an FDA-approved drug with over a century of medical use, and it is included on the World Health Organization’s List of Essential Medicines. MB has been safely administered in humans for the treatment of methemoglobinemia, malaria, and urinary tract infections, among others, at therapeutic doses far exceeding those used in topical applications [22].

Taken together, these findings highlight MB’s unique combination of safety, skin bioavailability, and mitochondrial protective activity, making it a particularly attractive agent for mitigating GLP-1 RA–associated or metabolically induced skin aging. For patients concerned about accelerated skin aging related to GLP-1RA therapy, MB-based creams may offer a novel therapeutic approach. Although still an emerging therapy, MB’s ability to restore mitochondrial function, promote collagen and elastin synthesis, and enhance skin hydration makes it a compelling option for preserving skin health in the context of metabolic or pharmacological stressors.

GLP-1 RA–Associated Hair Loss: Methylene Blue Mitigates GLP-1–Induced Cytotoxicity

Hair loss associated with GLP-1 RA is typically reversible and most often reflects telogen effluvium, a transient condition in which hair follicles enter a resting phase rather than being destroyed. Once the acute trigger, commonly rapid weight loss, resolves, normal hair growth usually resumes within several months. Gradual weight reduction, adequate protein intake, and correction of micronutrient deficiencies (biotin, iron, vitamin D, zinc) can support recovery. In some cases, dermatologists may suggest nutritional supplementation or topical minoxidil to accelerate regrowth, while a temporary adjustment in GLP-1 RA dosage may help stabilize shedding.

Recent findings provide mechanistic insight into the cellular basis of GLP-1 RA–associated alopecia [25]. Exposure of cultured human hair follicle stem cells (HFSCs) to GLP-1 led to premature apoptosis and mitochondrial dysfunction, consistent with a direct cytotoxic effect of GLP-1 signaling on follicular progenitors. Notably, pre-treatment with MB markedly reduced GLP-1–induced cell death, preserving HFSC viability, mitochondrial respiration, and redox balance. They further demonstrated that MB actively promotes HFSC proliferation and maintenance, supporting their long-term regenerative potential. Mechanistically, MB activates the canonical Wnt/ β-catenin signaling pathway, a critical regulator of hair follicle renewal, while concurrently protecting HFSCs from GLP-1–induced suppression of this pathway. Together, these findings identify MB as a dual-action modulator, both restoring mitochondrial health and reactivating regenerative signaling, that may safeguard follicular stem cell function and mitigate hair loss associated with GLP-1 RA therapy, reducing GLP–1–induced cell death, preserving HFSC viability and mitochondrial respiration.

Given that HFSCs serve as the reserve population responsible for replenishing dying or shed follicles, their loss may have long-term implications for follicular regeneration. While acute hair shedding in GLP-1 RA users often manifests as a reversible telogen effluvium, sustained or repeated insult to HFSCs could progressively diminish the follicle’s regenerative capacity. These findings highlight MB’s mitochondria-protective and antioxidant activity as a potential strategy not only to mitigate acute GLP-1-associated follicular stress but also to preserve long-term scalp and hair follicle homeostasis during therapy.

How about retinoids?

Retinoids (vitamin A derivatives) such as tretinoin and retinol remain the dermatologic gold standard for improving collagen synthesis and reducing wrinkles. They act through nuclear receptors to stimulate collagen and glycosaminoglycan production while suppressing matrix metalloproteinases (MMPs) and accelerating epidermal turnover [26,27]. However, this accelerated turnover comes at a cost, retinoids can deplete skin and hair follicle stem cell pools, impairing intrinsic regenerative pathways and increasing irritation and dryness [28]. Previous research indicates that vitamin A derivatives suppress the β-catenin signaling pathway in HFSCs, thereby reducing their proliferative and regenerative capacity [29].

SUMMARY

In summary, MB offers a promising therapeutic approach to counteract the mitochondrial and regenerative deficits associated with GLP-1 RA therapy. By restoring mitochondrial respiration, reducing oxidative stress, and activating the β-catenin signaling pathway, MB supports both dermal fibroblast and hair follicle stem cell function. These actions promote collagen and elastin synthesis, improve skin hydration and elasticity, and preserve the regenerative capacity of hair follicles. In patients experiencing skin thinning or hair shedding during GLP-1 RA treatment, MB-based topical formulations may provide a safe, well-tolerated, and mechanistically targeted intervention to maintain long-term skin vitality and hair density.

1. Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. E Clin Med. 2024; 75: 102782.
2. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384: 989-1002.
3. Mansour MR, Olivia H, Marissa Y, Emmanuel MN, Chaiyasate K. The rise of “Ozempic Face”: Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. J Plast Reconstr Aesthet Surg, 2024; 96: 225-227.
4. Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. J Am Acad Dermatol. 2025; 92: 1141-1143.
5. Light D, Arvanitis GM, Abramson D, Glasberg SB. Effect of weight loss after bariatric surgery on skin and the extracellular matrix. Plast Reconstr Surg. 2010; 125: 343-351.
6. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, Castro A, Cebrián-Cuenca A, de Torres-Sánchez A, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022; 12: 145.
7. Dumas SN, Ntambi JM. A Discussion on the Relationship between Skin Lipid Metabolism and Whole-Body Glucose and Lipid Metabolism: Systematic Review. J Cell Signal (Los Angel). 2018; 3: 189.
8. Manzoni AP, Weber MB. Skin changes after bariatric surgery. An Bras Dermatol. 2015; 90: 157-66.
9. Desai DD, Sikora M, Nohria A, Bordone L, Caplan AS, Shapiro J, et al. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024; 63: 1128-1130.
10. Kang DH, Kwon SH, Sim WY, Lew BL. Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 2024; 36: 384-388.
11. Park K. Role of micronutrients in skin health and function. Biomol Ther (Seoul). 2015; 23: 207-217.
12. Dopytalska K, Baranowska-Bik A, Roszkiewicz M, Bik W, Walecka I. The role of leptin in selected skin diseases. Lipids Health Dis. 2020; 19: 215.
13. Watabe R, Yamaguchi T, Kabashima-Kubo R, Yoshioka M, Nishio D, Nakamura M. Leptin controls hair follicle cycling. Exp Dermatol. 2014; 23: 228-229.
14. Trevor LV, Riches-Suman K, Mahajan AL, Thornton MJ. Adipose Tissue: A Source of Stem Cells with Potential for Regenerative Therapies for Wound Healing. J Clin Med. 2020; 9: 2161.
15. Xiong ZM, Choi JY, Wang K, Zhang H, Tariq Z, Wu D, et al. Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria. Aging Cell. 2016; 15: 279-290.
16. Lanza IR, Zabielski P, Klaus KA, Morse DM, Heppelmann CJ, Bergen HR 3rd, et al. Chronic caloric restriction preserves mitochondrial function in senescence without increasing mitochondrial biogenesis. Cell Metab. 2012; 16: 777-788.
17. Breininger SP, Malcomson FC, Afshar S, Turnbull DM, Greaves L, Mathers JC. Effects of obesity and weight loss on mitochondrial structure and function and implications for colorectal cancer risk. Proc Nutr Soc. 2019; 78: 426-437.
18. Wani M, Chakole S, Agrawal S, Gupta A, Chavada J, Pathade AG, et al. Unveiling Skin Manifestations: Exploring Cutaneous Signs of Malnutrition in Eating Disorders. Cureus. 2023; 15: e44759.
19. Sinha RA, Singh BK, Zhou J, Wu Y, Farah BL, Ohba K, et al. Thyroid hormone induction of mitochondrial activity is coupled to mitophagy via ROS-AMPK-ULK1 signaling. Autophagy. 2015; 11: 1341-1357.
20. Lin K, Dong C, Zhao B, Zhou B, Yang L. Glucagon-like peptide-1 receptor agonist regulates fat browning by altering the gut microbiota and ceramide metabolism. MedComm (2020). 2023; 4: e416.
21. Wretlind A, Curovic VR, de Zawadzki A, Suvitaival T, Xu J, Zobel EH, et al. Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials. Lipids Health Dis. 2023; 22: 160.
22. Xue H, Thaivalappil A, Cao K. The Potentials of Methylene Blue as an Anti-Aging Drug. Cells. 2021; 10: 3379.
23. Xiong ZM, Mao X, Trappio M, Arya C, Kordi JE, Cao K. Ultraviolet radiation protection potentials of Methylene Blue for human skin and coral reef health. Sci Rep. 2021; 11: 10871.
24. Xiong ZM, O’Donovan M, Sun L, Choi JY, Ren M, Cao K. Anti-Aging Potentials of Methylene Blue for Human Skin Longevity. Sci Rep. 2017; 7: 2475.
25. Kavitha S, Huijing X, Kan C, Methylene Blue Protects Hair Follicle Stem Cells from Oxidative and Metabolic Stress to Enhance Hair Regeneration. 2025.
26. Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006; 1: 327-348.
27. Kong R, Cui Y, Fisher GJ, Wang X, Chen Y, Schneider LM, Majmudar G. A comparative study of the effects of retinol and retinoic acid on histological, molecular, and clinical properties of human skin. J Cosmet Dermatol. 2016; 15: 49-57.
28. Ojeh N, Pastar I, Tomic-Canic M, Stojadinovic O. Stem Cells in Skin Regeneration, Wound Healing, and Their Clinical Applications. Int J Mol Sci. 2015; 16: 25476-25501.
29. Dillard AC, Lane MA. Retinol decreases beta-catenin protein levels in retinoic acid-resistant colon cancer cell lines. Mol Carcinog. 2007; 46: 315-329.